Evidence map›Paper›PMID 41890440›Full record

ArticleNew microbes and new infections2026

Incidence of azole resistance among clinical isolates of

Arnaud Fekkar, Marion Blaize, Sophie Cassaing, Boualem Sendid, Grégoire Pasquier, Sébastien Imbert, Christophe Hennequin, Françoise Botterel, Florent Morio, Jean Menotti and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Arnaud FekkarAP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Parasitologie Mycologie, F-75013, Paris, France.
Marion BlaizeAP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Parasitologie Mycologie, F-75013, Paris, France.
Sophie CassaingCentre Hospitalier Universitaire de Toulouse, Faculté de Santé, Hôpital Purpan, Parasitologie-Mycologie, Toulouse, France.
Boualem SendidCHU Lille, Institut de Microbiologie, Service de Parasitologie-Mycologie, INSERM U1285, CNRS UMR 8576, Université de Lille, Lille, F-59000, France.
Grégoire PasquierLaboratoire de Parasitologie-Mycologie, CHU de Montpellier, Université de Montpellier, CNRS, IRD, MiVEGEC, Montpellier, France.
Sébastien ImbertCentre Hospitalier Universitaire de Bordeaux, Service de Parasitologie - Mycologie, F-33075, Bordeaux, France.
Christophe HennequinAP-HP, Groupe Hospitalier Saint-Antoine, Parasitologie Mycologie, F-75013, Paris, France.
Françoise BotterelAP-HP, Groupe Hospitalier Henri Mondor, Parasitologie Mycologie, F-94000, Créteil, France.
Florent MorioNantes Université, CHU Nantes, Cibles et Médicaments des Infections et de l'Immunité, IICiMed, UR 1155, F-44000, Nantes, France.
Jean MenottiHospices Civils de Lyon et Université Claude Bernard-Lyon 1, Hôpital de la Croix-Rousse, Service de Parasitologie et de Mycologie Médicale, F-69004, Lyon, France.
Solène Le GalCHU de Brest, Laboratoire de Parasitologie-Mycologie, F-29609, Brest, France.
Eloise BaillyCHU de Dijon, Laboratoire de Parasitologie Mycologie, F-21000, Dijon, France.
Marie-Elisabeth BougnouxAP-HP, Groupe Hospitalier Necker-Enfants Malades, Parasitologie Mycologie, F-75013, Paris, France.
Antoine HugueninCHU de Reims, Laboratoire de Parasitologie Mycologie, F-51100, Reims, France.
Christine BonnalAPHP, Hôpital Bichat Claude Bernard, Parasitologie Mycologie, F-75018, Paris, France.
Milène SassoLaboratoire de Parasitologie-Mycologie, CHU Nîmes, Université de Montpellier, CNRS, IRD, MiVEGEC, Montpellier, France.
Aliosha FeussAP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Parasitologie Mycologie, F-75013, Paris, France.
Arnaud JabetAP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Parasitologie Mycologie, F-75013, Paris, France.
Alexandre GodmerSorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France.
Renaud PiarrouxAP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Parasitologie Mycologie, F-75013, Paris, France.
Anne-Cécile NormandAP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Parasitologie Mycologie, F-75013, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fluconazole-resistant isolates of Objective: Our objectives were to get an overview of the French epidemiology, to determine the incidence of azole resistance and to assess the genetic relationship between isolates. Methods: We initiated a prospective national multicenter study (ReCap - Resistance of Results: Between May 2022 and February 2024, a total of 2,602 isolates were collected from 1,830 patients. Among these, 392 isolates (15.1%) from 184 patients (10%) were found to be resistant (MIC >4 mg/L). Percentage of patients colonized or infected by a resistant isolate ranged from 0 to 54.4% across centers. Genotyping analysis performed on 1,320 isolates showed high diversity among susceptible isolates and indicated that two fluconazole-resistant clusters are circulating in different hospitals of the Paris area. Cross-resistance occurred frequently with voriconazole resistance observed in 62.9% (73/116) of fluconazole-resistant isolates. Conclusion: In France, the frequency of resistance to fluconazole reaches 10% of patients harboring

Indexed as

ClusterEmergenceFluconazoleFungal infectionGlobal healthMultidrug resistancePosaconazoleVoriconazole

Identifiers

PMID41890440
PMCPMC13014649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.